Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tabalumab plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in previously treated multiple myeloma
2011-005103-32Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of tabalumab in multiple myeloma (MM), sponsored by Eli Lilly and Company. Started Apr 2012; status: completed.
02
Drugs
tabalumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2011-005103-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005103-32.